| (Values in U.S. Thousands) | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 |
| Sales | -9,999,000 | 7,030 | 6,020 | 5,750 | 5,200 |
| Sales Growth | -142,333.27% | +16.78% | +4.70% | +10.58% | -25.93% |
| Net Income | -9,999,000 | -8,340 | -6,620 | -8,510 | -6,330 |
| Net Income Growth | -119,792.09% | -25.98% | +22.21% | -34.44% | -13.24% |
Cardiome Pharma Corp (CRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.